[Role of leptin and leptin resistance in non-alcoholic fatty liver disease development in persons with obesity and overweight].
OBJECTIVE
To study the impact of leptin and leptinresistance on formation of non-alcoholic fatty liver disease (NAFLD) of people with obesity and overweight.


METHODS
105 patients with obesity and overweight were examined, among them 19 men and 86 women, median age 58 (50-63) years. Risk factors development NAFLD, anthropometric indices, biochemical analysis of blood, abdominal ultrasonic studies, levels leptin and its soluble receptor were estimated. examined people with NAFLD were included into 2 groups: main group (patients NAFLD, n = 77) and comparison group (n = 28).


RESULTS
Waist volume, body mass index, blood glucose were higher in group of patients with NAFLD (p < 0.0001, p < 0.003, p < 0.00002, level) and had positive connection with the change in liver development (rs = (0.376), p < 0.00008, rs = (0.293), p < 0.002, rs = (0.417), p < 0.00001, level). Leptin has direct dependence (rs = (0.291), p < 0.027), while level of soluble receptors to leptin was of reverse dependence (rs = (-0.456), p < 0.0003) on the degree of body weight. Between these indicators in the group with obesity and overweight negative correlation of moderate strength (rs = (-0.370), p < 0.004) was revealed. There were tendencies to a higher level leptin and lower level receptor to leptin in group with NAFLD (median level leptin 29.20 (12.63-44.98) in main group against 27.49 (12.05-54.79), median receptor to leptin 18.25 (14.69-24.26) against 22.05 (14.57-32.04), respectively). However these indicators in the main group also had a negative correlation bond of moderate strength (rs = (-0.384), p < 0.007).


CONCLUSIONS
Development of NAFLD are associated with obesity and excess body weight, phenomenon of leptinresistance arises to patients with obesity and can be considered as predictor of the development and progression of NAFLD among this category of patients.
M A
MA
Livzan
I V
IV
Lapteva
T S
TS
Miller
D015992:Body Mass Index; D016022:Case-Control Studies; D015331:Cohort Studies; D005260:Female; D006801:Humans; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000000981:diagnostic imaging / Q000209:etiology* / Q000378:metabolism; D009765:Obesity / Q000150:complications* / Q000000981:diagnostic imaging / Q000378:metabolism; D050177:Overweight / Q000150:complications / Q000000981:diagnostic imaging / Q000378:metabolism; D054411:Receptors, Leptin / Q000097:blood*; D014463:Ultrasonography
D020738:Leptin; D054411:Receptors, Leptin